Table 2. Summary results of the subgroup analysis for the effect of treatment modality on BCVA.
| Variables | MD | 95% CI | I2, % | No. of studies |
|---|---|---|---|---|
| ME type | ||||
| RVO-ME | 6.59 | -4.64,17.82 | 0 | 2 |
| DME | -4.18 | -6.68, -1.69 | 0 | 6 |
| Different drugs | ||||
| Ranibizumab | -7.30 | -11.78, -2.82 | 0 | 3 |
| Bevacizumab | -2.18 | -5.09,0.72 | 0 | 4 |
| Study time | ||||
| ≤6 months | -4.20 | -7.88, -0.52 | 20 | 5 |
| >6 months | -1.80 | -7.09,3.50 | 0 | 2 |
Abbreviations: BCVA = best corrected visual acuity; DME = diabetic macular edema; RVO-ME = macular edema secondary to branch retinal vein occlusion; ME = macular edema; CI = confidence interval; MD = mean difference.